The collaboration between several teams from AP-HP, l’IGMM Institut de Génétique Moléculaire de Montpellier (CNRS/Université de Montpellier) and Metafora-Biosystems is a success: for the first time, a diagnostic test, METAglut1, has received a positive decision from Haute Autorité de Santé permitting the reimbursement of its costs by health insurance companies.
METAglut1, a fast, reliable blood test, provides an early diagnosis of Glut1 deficiency syndrome, or De Vivo disease, a rare and disabling neurological condition.
Haute Autorité de Santé – Forfait innovation : le dispositif porte ses fruits (has-sante.fr)
https://n.neurology.org/content/100/23/e2360
https://finance.yahoo.com/news/metafora-test-early-diagnosis-vivo-130000663.html
